Biotech Roundup: Biogen Rumors, Theranos, Electro-Drugs & More
Xconomy
AUGUST 5, 2016
Then came the rumor mill: Companies may or may not be approaching Biogen about a sale, and Biogen may or may not be fielding offers. Published in January, the technology comes from the lab of Keith Joung, who is an Editas cofounder. Strimvelis is a treatment for severe combined immune deficiency, commonly known as “bubble boy” disease.
40 
Let's personalize your content